Condition
Primary Glioblastoma Multiforme
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03423628Phase 1Active Not Recruiting
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT00574964Phase 2TerminatedPrimary
Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme
Showing all 2 trials